

The Applicants herein elect group I above (claims 22-33 drawn to a pharmaceutical composition comprising α interferon B/D hybrid contained in a liposome, classified in class 424, subclass 85.1) with traverse for prosecution in the current examination.

REMARKS

Applicants have elected group I above, which is drawn to a pharmaceutical composition comprising α interferon B/D hybrid contained in a liposome, for prosecution in the case.


Examiner has not indicated why the prosecution of all claims in the application presents a serious burden for prosecution. Applicants believe that the subject matter of the galenic composition represented in claims 22-33 and the subject matter of the process represented in method claim 33 are related and freely searchable. Thus simultaneous examination of all claims in the present application should present no extraordinary effort for prosecution. Applicants therefore respectfully request that the Examiner withdraw the present restriction requirement.

Alternatively, Applicants herein reserve their right to elect prosecution of the presently unelected invention of claim 33 for further prosecution in the future.

Applicants respectfully request entry of this response to restriction requirement and favorable consideration of the claims in light thereof. No fee is believed due in this Application however the Examiner is authorized to charge any additional fees which may be due under 37 C.F.R. 1.17 or credit any overpayment to Account No. 19-0134 in the name of Novartis Corporation. If it will advance prosecution of this matter the Examiner is encouraged to contact the Applicants' undersigned counsel at the phone number listed below.

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Building 430
East Hanover, NJ 07936-1080
(862) 778-7960


Edward J. Wilusz, Jr.
Attorney for Applicants
Reg. No. 52,370

Date: September 26, 2003